Cargando…
The Consortium for the early identification of Alzheimer's disease–Quebec (CIMA-Q)
INTRODUCTION: The Consortium for the early identification of Alzheimer's disease–Quebec (CIMA-Q) created a research infrastructure to recruit, characterize, and track disease progression in individuals at risk of dementia. METHODS: CIMA-Q established standardized clinical, neuropsychological, n...
| Autores principales: | , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Elsevier
2019
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6880140/ https://www.ncbi.nlm.nih.gov/pubmed/31788534 http://dx.doi.org/10.1016/j.dadm.2019.07.003 |
| _version_ | 1783473707191107584 |
|---|---|
| author | Belleville, Sylvie LeBlanc, Andréa C. Kergoat, Marie-Jeanne Calon, Frédéric Gaudreau, Pierrette Hébert, Sébastien S. Hudon, Carol Leclerc, Nicole Mechawar, Naguib Duchesne, Simon Gauthier, Serge |
| author_facet | Belleville, Sylvie LeBlanc, Andréa C. Kergoat, Marie-Jeanne Calon, Frédéric Gaudreau, Pierrette Hébert, Sébastien S. Hudon, Carol Leclerc, Nicole Mechawar, Naguib Duchesne, Simon Gauthier, Serge |
| author_sort | Belleville, Sylvie |
| collection | PubMed |
| description | INTRODUCTION: The Consortium for the early identification of Alzheimer's disease–Quebec (CIMA-Q) created a research infrastructure to recruit, characterize, and track disease progression in individuals at risk of dementia. METHODS: CIMA-Q established standardized clinical, neuropsychological, neuroimaging, blood (plasma, serum, RNA, genomic DNA), cryopreserved peripheral blood mononuclear cells, and cerebrospinal fluid collection protocols. These data and biological materials are available to the research community. RESULTS: In phase 1, 115 persons with subjective cognitive decline, 88 with mild cognitive impairment, 31 with early probable Alzheimer's disease, and 56 older adults with no worries nor impairments received detailed clinical and cognitive evaluations as well as blood and peripheral blood mononuclear cells collections. Among them, 142 underwent magnetic resonance imaging, 29 a (18)fluorodeoxyglucose positron emission tomography, and 60 a lumbar puncture. DISCUSSION: CIMA-Q provides procedures and resources to identify early biomarkers and novel therapeutic targets, and holds promise for detecting cognitive decline in Alzheimer's disease. |
| format | Online Article Text |
| id | pubmed-6880140 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2019 |
| publisher | Elsevier |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-68801402019-11-29 The Consortium for the early identification of Alzheimer's disease–Quebec (CIMA-Q) Belleville, Sylvie LeBlanc, Andréa C. Kergoat, Marie-Jeanne Calon, Frédéric Gaudreau, Pierrette Hébert, Sébastien S. Hudon, Carol Leclerc, Nicole Mechawar, Naguib Duchesne, Simon Gauthier, Serge Alzheimers Dement (Amst) Diagnostic Assessment & Prognosis INTRODUCTION: The Consortium for the early identification of Alzheimer's disease–Quebec (CIMA-Q) created a research infrastructure to recruit, characterize, and track disease progression in individuals at risk of dementia. METHODS: CIMA-Q established standardized clinical, neuropsychological, neuroimaging, blood (plasma, serum, RNA, genomic DNA), cryopreserved peripheral blood mononuclear cells, and cerebrospinal fluid collection protocols. These data and biological materials are available to the research community. RESULTS: In phase 1, 115 persons with subjective cognitive decline, 88 with mild cognitive impairment, 31 with early probable Alzheimer's disease, and 56 older adults with no worries nor impairments received detailed clinical and cognitive evaluations as well as blood and peripheral blood mononuclear cells collections. Among them, 142 underwent magnetic resonance imaging, 29 a (18)fluorodeoxyglucose positron emission tomography, and 60 a lumbar puncture. DISCUSSION: CIMA-Q provides procedures and resources to identify early biomarkers and novel therapeutic targets, and holds promise for detecting cognitive decline in Alzheimer's disease. Elsevier 2019-11-20 /pmc/articles/PMC6880140/ /pubmed/31788534 http://dx.doi.org/10.1016/j.dadm.2019.07.003 Text en © 2019 The Authors http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). |
| spellingShingle | Diagnostic Assessment & Prognosis Belleville, Sylvie LeBlanc, Andréa C. Kergoat, Marie-Jeanne Calon, Frédéric Gaudreau, Pierrette Hébert, Sébastien S. Hudon, Carol Leclerc, Nicole Mechawar, Naguib Duchesne, Simon Gauthier, Serge The Consortium for the early identification of Alzheimer's disease–Quebec (CIMA-Q) |
| title | The Consortium for the early identification of Alzheimer's disease–Quebec (CIMA-Q) |
| title_full | The Consortium for the early identification of Alzheimer's disease–Quebec (CIMA-Q) |
| title_fullStr | The Consortium for the early identification of Alzheimer's disease–Quebec (CIMA-Q) |
| title_full_unstemmed | The Consortium for the early identification of Alzheimer's disease–Quebec (CIMA-Q) |
| title_short | The Consortium for the early identification of Alzheimer's disease–Quebec (CIMA-Q) |
| title_sort | consortium for the early identification of alzheimer's disease–quebec (cima-q) |
| topic | Diagnostic Assessment & Prognosis |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6880140/ https://www.ncbi.nlm.nih.gov/pubmed/31788534 http://dx.doi.org/10.1016/j.dadm.2019.07.003 |
| work_keys_str_mv | AT bellevillesylvie theconsortiumfortheearlyidentificationofalzheimersdiseasequebeccimaq AT leblancandreac theconsortiumfortheearlyidentificationofalzheimersdiseasequebeccimaq AT kergoatmariejeanne theconsortiumfortheearlyidentificationofalzheimersdiseasequebeccimaq AT calonfrederic theconsortiumfortheearlyidentificationofalzheimersdiseasequebeccimaq AT gaudreaupierrette theconsortiumfortheearlyidentificationofalzheimersdiseasequebeccimaq AT hebertsebastiens theconsortiumfortheearlyidentificationofalzheimersdiseasequebeccimaq AT hudoncarol theconsortiumfortheearlyidentificationofalzheimersdiseasequebeccimaq AT leclercnicole theconsortiumfortheearlyidentificationofalzheimersdiseasequebeccimaq AT mechawarnaguib theconsortiumfortheearlyidentificationofalzheimersdiseasequebeccimaq AT duchesnesimon theconsortiumfortheearlyidentificationofalzheimersdiseasequebeccimaq AT gauthierserge theconsortiumfortheearlyidentificationofalzheimersdiseasequebeccimaq AT theconsortiumfortheearlyidentificationofalzheimersdiseasequebeccimaq AT bellevillesylvie consortiumfortheearlyidentificationofalzheimersdiseasequebeccimaq AT leblancandreac consortiumfortheearlyidentificationofalzheimersdiseasequebeccimaq AT kergoatmariejeanne consortiumfortheearlyidentificationofalzheimersdiseasequebeccimaq AT calonfrederic consortiumfortheearlyidentificationofalzheimersdiseasequebeccimaq AT gaudreaupierrette consortiumfortheearlyidentificationofalzheimersdiseasequebeccimaq AT hebertsebastiens consortiumfortheearlyidentificationofalzheimersdiseasequebeccimaq AT hudoncarol consortiumfortheearlyidentificationofalzheimersdiseasequebeccimaq AT leclercnicole consortiumfortheearlyidentificationofalzheimersdiseasequebeccimaq AT mechawarnaguib consortiumfortheearlyidentificationofalzheimersdiseasequebeccimaq AT duchesnesimon consortiumfortheearlyidentificationofalzheimersdiseasequebeccimaq AT gauthierserge consortiumfortheearlyidentificationofalzheimersdiseasequebeccimaq AT consortiumfortheearlyidentificationofalzheimersdiseasequebeccimaq |